Genotoxicity of anti-tumor necrosis factor therapy in patients with juvenile idiopathic arthritis

Arthritis Care Res (Hoboken). 2010 Jan 15;62(1):73-7. doi: 10.1002/acr.20016.

Abstract

Objective: To assess the possible effects of both inflammation and the anti-tumor necrosis factor agents (anti-TNF) on DNA damage with a specific assay, and their effects on the repair capacity of DNA.

Methods: From a group of 20 children with juvenile idiopathic arthritis (JIA), 16 patients who completed the study and 16 control subjects were evaluated. DNA damage and repair capacity were analyzed by the comet assay at the level of peripheral lymphocytes before anti-TNF (etanercept) injections and on the 15th, 90th, and 180th days after the first injection.

Results: The amount of damage as detected by the aforementioned assay was higher in patients with JIA compared with controls. On the 15th day after the initial anti-TNF injection, there was a decrease in the mean DNA tail length of JIA patients, however on the 90th day an increase was observed; thereafter, an upward trend was observed until the end of the study. JIA patients had a DNA repair capacity that was significantly less than that of controls.

Conclusion: The results of the comet technique suggests that JIA patients already have increased basal DNA damage before anti-TNF therapy; they are more sensitive to the DNA damage produced by H(2)O(2), and have a less efficient DNA repair system in comparison with control cells. After an initial improvement at 2 weeks, parameters of genotoxicity worsened, and DNA repair was further impaired 6 months after the addition of an anti-TNF agent to treatment.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / pharmacology
  • Arthritis, Juvenile / drug therapy*
  • Arthritis, Juvenile / genetics*
  • Child
  • Child, Preschool
  • Comet Assay
  • DNA Damage / drug effects
  • DNA Damage / genetics*
  • DNA Repair / drug effects
  • DNA Repair / genetics*
  • Female
  • Humans
  • Male
  • Methotrexate / adverse effects
  • Methotrexate / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Methotrexate